Clinical Course of Liver Cirrhosis in Torch-infected Patients and the Possibility of Correction Using “Polyana Kvasova” Mineral Water

Abstract

Aim: To investigate the peculiarities of clinical and laboratory changes in liver cirrhosis in TORCH-infected patients and their dynamics against the background of complex therapy with the use of Polyana Kvasova mineral water (MW). Materials and Methods: 64 patients with alcohol-related LC were examined. The study was carried out in two stages. At the 1st stage, the examined patients with LC were divided into two groups depending on the presence or absence of TORCH infections to determine the characteristics of the clinical course of LC in these patients. Group I included patients with LC (n=30), who were not diagnosed with TORCH infection, and group II included patients with LC who tested positive for antibodies to infections of the TORCH group (n=34). The data of patients of group II were divided into two subgroups, depending on the treatment performed. Patients of subgroup IIA (n=16) received only basic therapy (BT), and patients of subgroup IIB (n=18) were additionally prescribed 100 ml of warm, still carbonated bicarbonate-sodium Polyana Kvasova mineral water (MW), 15-20 minutes before meals 6 times a day. The duration of the treatment and observation of patients at the second stage of the study was 1 month. Results: In patients with LC of group II, signs of jaundice, pain and dyspeptic syndromes were statistically significantly more often detected - p<0.05. In group II of patients with LC, a more pronounced, statistically significant increase in the indicators of cholestatic syndrome. A more significant reduction in the manifestations of dyspeptic and pain syndrome, as well as the severity of jaundice, was observed in LC patients of the IIB subgroup who, in addition to BT, were prescribed Polyana Kvasova MW. A significant decrease in laboratory markers of cholestatic syndrome was established (TBIL level by 20.0±0.6 mmol/L; ALP by 84.0±1.8 IU/L, GGT by 48.7±1.5 U/L) in the subgroup of patients, who in addition to BT were prescribed MW. Conclusions: 1. In TORCH-infected patients, alcohol-related liver cirrhosis is more often detected at the stage of subcompensation (class C according to Child-Pugh) and is clinically detected by signs of dyspeptic and pain syndromes, as well as laboratory manifestations of cholestatic syndrome and jaundice syndrome. 2. The use of Polyana Kvasova MW as part of the complex therapy of patients with alcohol-related liver cirrhosis in combination with TORCH infection is a pathogenetically based and safe method for reducing the severity of dyspeptic and pain syndromes, as well as clinical and laboratory signs of jaundice in these patients.